Company news

Rein Therapeutics, Inc. news in 2024

Rein Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 13, 2024

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

November 12, 2024

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

October 30, 2024

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

October 11, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

September 22, 2024

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

August 13, 2024

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

July 29, 2024

Aileron Therapeutics to be Included in the Russell Microcap® Index

June 30, 2024

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

May 5, 2024

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

May 2, 2024

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

April 30, 2024

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

April 30, 2024

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 14, 2024

Aileron Therapeutics Announces CEO Transition

March 11, 2024

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

February 14, 2024

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

January 31, 2024